ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia

Company expects to announce top-line results late Q3 or early Q4 2014

Coppell, Texas – July 14, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has completed enrollment in ZS004, its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate),

Read More

Otonomy Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, July 14, 2014 /PRNewswire/ – Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.

Read More

ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9

Applications cover composition of matter and methods of treating hyperkalemia and carry a patent term to at least 2032

Coppell, Texas – July 8, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Numbers 13/371,080 and 14/036,489 for ZS-9 (sodium zirconium cyclosilicate), the Company’s product candidate in Phase 3 development for the treatment of hyperkalemia.

Read More

ZS Pharma Announces Start of Enrollment of Phase 3 Long-Term Maintenance Study of ZS-9 in Patients with Hyperkalemia

–Open-Label Safety Study Evaluating Long-Term Safety and Efficacy of Oral Investigational Hyperkalemia Treatment—

Coppell, Texas – June 26, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has begun enrolling patients in ZS005, a Phase 3 open-label, 12-month, long-term maintenance study of ZS-9, an investigational treatment for hyperkalemia.

Read More
Web-Pick